The authors present the case of an obese patient with advanced heart failure that demonstrates the paradox between obesity and heart failure prognosis. In addition, the authors discuss the rationale for the correction of cardiopulmonary stress data (used as predictors of survival and listing for cardiac transplantation) for lean weight (as opposed to total body weight), a consideration that may be particularly important in obese patients with a high percentage of body fat.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1527-5299.2007.06248.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chromatin State Maps of Blood Pressure-Relevant Renal Segments Reveal Potential Regulatory Role for SNPs.
Hypertension
December 2024
Versiti Blood Research Institute, Milwaukee, WI (A.R., C.S., S.R.).
Background: Hypertension or elevated blood pressure (BP) is a worldwide clinical challenge and the leading primary risk factor for kidney dysfunctions, heart failure, and cerebrovascular disease. The kidney is a central regulator of BP by maintaining sodium-water balance. Multiple genome-wide association studies revealed that BP is a heritable quantitative trait, modulated by several genetic, epigenetic, and environmental factors.
View Article and Find Full Text PDF"Letter to the Editor: A Correction to [Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation]".
Clin Cardiol
January 2025
Alexandria University, Alexandria faculty of Medicine, Champollion street, Alexandria, Egypt.
We recently reviewed the article titled "Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation" published in Clinical Cardiology by [khan et al.] (1) with great interest. This study addresses a crucial area of clinical practice, and we appreciate the authors' efforts in exploring this topic.
View Article and Find Full Text PDFAssessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials.
Diabetes Obes Metab
December 2024
The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Aim: To comprehensively evaluate the benefits and risks of glucagon-like peptide-1 receptor agonists (GLP-1RA), dipeptidyl peptidase 4 inhibitors (DPP4i), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Materials And Methods: A systematic search of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to November 2023 to identify randomized cardiovascular and kidney outcome trials that enrolled adults with type 2 diabetes, heart failure, or chronic kidney disease and compared DPP4i, GLP-1RAs, or SGLT2i to placebo. Twenty-one outcomes (e.
The Cardiovascular Protective Function of Natural Compounds Through AMPK/SIRT1/PGC-1α Signaling Pathway.
Food Sci Nutr
December 2024
Department of Pharmacodynamics and Toxicology, School of Pharmacy Mashhad University of Medical Sciences Mashhad Iran.
Cardiovascular disease (CVD) poses a major risk to human health and exert a heavy burden on individuals, society, and healthcare systems. Therefore, it is critical to identify CVD's underlying mechanism(s) and target them using effective agents. Natural compounds have shown promise as antioxidants with cardioprotective functions against CVD injuries due to their antioxidative solid capacity and high safety profile.
View Article and Find Full Text PDFIntegrated multi-omics analysis describes immune profiles in ischemic heart failure and identifies PTN as a novel biomarker.
Front Mol Biosci
December 2024
Department of Nephrology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Introduction: Heart failure is a leading global cause of mortality, with ischemic heart failure (IHF) being a major contributor. IHF is primarily driven by coronary artery disease, and its underlying mechanisms are not fully understood, particularly the role of immune responses and inflammation in cardiac muscle remodeling. This study aims to elucidate the immune landscape of heart failure using multi-omics data to identify biomarkers for preventing cardiac fibrosis and disease progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!